HER2-positive early breast cancer patients with residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles. Here, ERBB2 is linked to breast carcinoma.